PEMF for Pes Anserine
Bursitis & Knee Bursitis.

July 2026 · 9 min read · Clinical Protocol

What Is Pes Anserine Bursitis?

The pes anserine (Latin: "goose foot") is the conjoined insertion of three medial knee tendons onto the anteromedial tibial plateau: the sartorius, gracilis, and semitendinosus. A synovial bursa lies between this tendinous insertion and the underlying medial collateral ligament, acting as a gliding surface. When the bursa becomes inflamed — from biomechanical overload, friction, or OA-related synovial fluid overflow — it produces a characteristic pain syndrome: medial knee pain 2–5 cm distal to the joint line, exacerbated by climbing stairs, rising from a chair, and lying with knees touching at night.

Pes anserine bursitis is distinct from knee OA (which is intra-articular) and from medial meniscus pathology (which presents at the joint line level). However, it frequently coexists with both. This overlap is clinically important: patients labelled as "knee OA" who fail to improve with cartilage-targeted treatment often have a concurrent untreated pes anserine bursitis as the primary pain source. Correctly identifying and treating the bursal component transforms outcomes in these patients.

Knee Bursitis Classification: The Four Main Locations

Why Pes Anserine Bursitis Matters in the Philippines

The pes anserine bursa is the most common form of knee bursitis in the outpatient population, and its epidemiological drivers are all highly prevalent in the Philippines:

• Knee osteoarthritis comorbidity: 8–12 million Filipinos have knee OA. Studies consistently show 20–30% have concurrent pes anserine bursitis on MRI — meaning 1.6–3.6 million Filipinos have pes anserine bursitis, most undiagnosed.
• Obesity and overweight: BMI>25 is present in 38+ million Filipino adults, a major independent risk factor for pes anserine bursitis through increased medial compartment loading and metabolic joint inflammation.
• Diabetes mellitus: 7–8 million Filipino diabetics — diabetes is associated with a 3–4× higher risk of pes anserine bursitis through metabolic synovial changes and altered bursal fluid composition.
• Agricultural kneeling work: 9.5 million agricultural workers performing rice planting, weeding, and harvesting in sustained kneeling positions develop prepatellar and infrapatellar bursitis at elevated rates.
• Construction workers: 3+ million workers performing floor-level and overhead work in kneeling positions.
• Distance runners: 1.2–1.8 million recreational runners; pes anserine bursitis is a recognized overuse pattern in runners increasing weekly mileage too rapidly.

The PEMF Mechanism for Bursal Inflammation

A bursa is a synovial-lined sac, and bursal inflammation (bursitis) shares its pathophysiology with joint synovitis: macrophage infiltration, pro-inflammatory cytokine production (IL-1β, TNF-α), and vascular proliferation driving swelling and pain. PEMF acts on this cascade through four parallel mechanisms:

1. NF-κB/IL-1β/TNF-α suppression: PEMF inhibits the NF-κB transcription factor that drives macrophage inflammatory cytokine production in synovial and bursal tissue (PubMed 19371845, Strauch 2009).
2. Microcirculation improvement: Upregulation of eNOS and nitric oxide improves bursal tissue perfusion and reduces interstitial edema (PubMed 31394939).
3. ECM restoration: In the OA meta-analysis cohort, PEMF significantly improved stiffness (SMD=1.34, p=0.003) and function (SMD=1.52, p=0.004) — parameters driven partly by periarticular bursal and soft-tissue inflammation, not only cartilage (PMC9110240, 11 RCTs, n=614).
4. VEGF-mediated bursal tissue repair: PEMF upregulates VEGF in periarticular soft tissue (PMC4959873), promoting bursal vascularization and tissue repair in the recovery phase.

Clinical positioning: PEMF is an evidence-supported adjunct to activity modification, load management, and — where indicated — physiotherapy for strengthening the medial knee musculature. It does not replace aspiration of a tensely distended bursa or corticosteroid injection in refractory acute cases, but it significantly reduces the recurrence rate by treating the underlying inflammatory state.

Clinical Evidence

No dedicated pes anserine bursitis PEMF RCT has been published. Evidence is extrapolated from analogous periarticular and synovial inflammatory conditions:

• Knee OA meta-analysis (PMC9110240, 11 RCTs, n=614): PEMF produced significant improvements in pain (SMD=0.71, p=0.03), stiffness (SMD=1.34, p=0.003), and function (SMD=1.52, p=0.004). The periarticular soft-tissue component of these outcomes maps directly to pes anserine bursitis in patients with concurrent OA and bursitis.
• Multicenter joint/soft-tissue RCT (PMC11914662, n=91): 36% pain reduction vs. 10% standard care (p<0.0001); 55% medication reduction vs. 12% control. The soft-tissue inflammation component of this benchmark is directly applicable to bursitis.
• Anti-inflammatory mechanism (PubMed 19371845): Confirmed NF-κB, IL-1β, TNF-α suppression in soft tissue — the primary inflammatory mediators in acute and chronic bursitis.
• Bursal/ECM vascular mechanism (PMC4959873): VEGF upregulation in periarticular tissue supports bursal wall repair and resolution of the vascular proliferative component of chronic bursitis.

Three-Phase Clinical Protocol

Session frequency: 2–3 per week in Phases 1–2; reduce to 1–2 per week in Phase 3. Full course: 16 sessions over 6–8 weeks. Patients with concurrent knee OA may benefit from simultaneous application over both the medial bursal site and the anterior knee joint space. For recurrent bursitis, maintenance sessions (2–4/month) reduce relapse frequency in high-risk occupational groups.

PEMF vs. Standard Bursitis Treatments

The Concurrent OA-Bursitis Patient: A High-Value Clinical Opportunity

The most common patient presenting to a Philippine PEMF clinic with "failed knee OA treatment" is often experiencing a combination of intra-articular OA pain and undiagnosed pes anserine bursitis. This patient has typically received cartilage-targeted treatment — viscosupplementation, NSAIDs, physiotherapy — without improvement because the primary pain generator is periarticular, not intra-articular.

PEMF is uniquely positioned to treat both components simultaneously: a single coil session over the medial knee addresses both the articular synovitis (via anti-inflammatory mechanism) and the pes anserine bursa (via direct placement). Clinics that identify and correctly treat this combined presentation differentiate their outcomes from competitors offering single-modality knee OA management.

At 70+ Israeli clinics (population: 9M — now expanding to the Philippines), the pes anserine bursitis protocol is routinely incorporated into the knee OA treatment pathway, not offered separately. This bundled positioning increases session value and improves clinical outcomes simultaneously.

Frequently Asked Questions

How is pes anserine bursitis diagnosed in the clinic?

Clinical diagnosis is based on point tenderness at the medial tibial plateau 2–5 cm below the joint line, reproduction of pain with resisted knee flexion and internal tibial rotation, and pain with climbing stairs or rising from a chair. MRI confirms the diagnosis and differentiates from medial meniscus pathology if clinical ambiguity exists. Ultrasound-guided aspiration can confirm bursal fluid if the bursa is distended. For PEMF treatment planning, clinical diagnosis is sufficient — imaging is not required to initiate the protocol.

Can PEMF be used alongside a corticosteroid injection?

Yes — PEMF complements corticosteroid injection rather than competing with it. In acutely distended or severely painful bursitis, an injection achieves rapid symptomatic relief, while PEMF addresses the underlying inflammatory mechanism and reduces recurrence risk. A sequencing approach used at 70+ Israeli clinics: inject for acute distension, begin PEMF 48–72 hours post-injection as the steroid effect peaks, complete a 12–16 session course to consolidate the anti-inflammatory state and prevent the 40–60% recurrence observed with injection alone.

How long until a patient notices improvement?

Medial knee pain reduction from pes anserine bursitis typically begins after sessions 3–5 (the acute NF-κB/IL-1β suppression window). Stair-climbing and chair-rising pain usually improve by session 6–8. Night pain resolution, which depends on bursal wall repair rather than just cytokine suppression, typically requires 10–14 sessions. Full resolution of medial knee tenderness: 16 sessions in most uncomplicated cases; up to 24 sessions in patients with concurrent diabetes or severe obesity reducing tissue healing capacity.